2024
Considerations when prescribing opioid agonist therapies for people living with HIV
Tarfa A, Lier A, Shenoi S, Springer S. Considerations when prescribing opioid agonist therapies for people living with HIV. Expert Review Of Clinical Pharmacology 2024, 17: 549-564. PMID: 38946101, PMCID: PMC11299801, DOI: 10.1080/17512433.2024.2375448.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidAnti-HIV AgentsBuprenorphineDelayed-Action PreparationsDelivery of Health CareDrug InteractionsHealth Services AccessibilityHIV InfectionsHumansMethadoneNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPre-Exposure ProphylaxisUnited StatesConceptsOpioid agonist therapyOpioid use disorderAntiretroviral therapyAgonist therapyDiagnosed OUDOpioid use disorder managementUse disorderTreatment of opioid use disorderExtended-release naltrexonePotential drug interactionsOpioid use disorder treatmentPrescribed opioid agonist therapyLong-acting formulationPre-exposure prophylaxisOUD outcomesImprove HIV preventionIntersection of HIVOpioid antagonistHIV outcomesHIV epidemicOpioidHIVOpioid use disorder servicesPWHHIV prevention
2022
Willingness to Be Vaccinated Against COVID-19 Among People With HIV in the United States: Results From a National Survey
Wickersham JA, Meyer JP, Shenoi S, Altice FL, Barakat LA, Virata M, Olivares M, Maviglia F, Khati A, Shrestha R. Willingness to Be Vaccinated Against COVID-19 Among People With HIV in the United States: Results From a National Survey. Frontiers In Medicine 2022, 9: 886936. PMID: 35847816, PMCID: PMC9280331, DOI: 10.3389/fmed.2022.886936.Peer-Reviewed Original ResearchCOVID-19 infectionCOVID-19 vaccineCOVID-19Undetectable HIV viral loadCOVID-19 vaccination uptakeAnnual influenza vaccinationHIV viral loadVaccine-related concernsNational surveyHIV careInfluenza vaccinationVaccination uptakeViral loadVaccination programSevere diseasePWHVaccineHIVInfectionIntensive outreach effortsTotal populationUnited StatesParticipantsAnnual incomeVast majorityCOVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey
Shrestha R, Meyer JP, Shenoi S, Khati A, Altice FL, Mistler C, Aoun-Barakat L, Virata M, Olivares M, Wickersham JA. COVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey. Vaccines 2022, 10: 424. PMID: 35335054, PMCID: PMC8949562, DOI: 10.3390/vaccines10030424.Peer-Reviewed Original ResearchCOVID-19 vaccine hesitancyVaccine hesitancySevere COVID-19 diseaseMean timeSample of PWHCells/mm3COVID-19 historyVaccine-related concernsGreater vaccine hesitancyCOVID-19 vaccineCOVID-19COVID-19 diseaseLower vaccine hesitancyCross-sectional online surveyCD4 countAssociated FactorsSide effectsHIVKey populationsPWHMultivariate linear regressionVaccineCOVID-19 epidemicHesitancyMost participants
2021
Cumulative burden of non-communicable diseases predicts COVID hospitalization among people with HIV: A one-year retrospective cohort study
Virata MD, Shenoi SV, Ladines-Lim J, Villanueva MS, Barakat LA. Cumulative burden of non-communicable diseases predicts COVID hospitalization among people with HIV: A one-year retrospective cohort study. PLOS ONE 2021, 16: e0260251. PMID: 34851963, PMCID: PMC8635326, DOI: 10.1371/journal.pone.0260251.Peer-Reviewed Original ResearchConceptsOne-year retrospective cohort studyCohort of PWHNon-communicable comorbiditiesPredictors of hospitalizationRetrospective cohort studyChronic lung diseaseLikelihood of hospitalizationSingle-site experienceCOVID-19 infectionNon-communicable diseasesOutcomes of peopleCohort studyHIV diseaseOverall mortalityClinical outcomesLung diseaseCardiovascular diseaseHospitalizationCumulative burdenHIVLater timeframeDiseaseEarly epidemicPWHOutcomes